Taranabant

What Does Taranabant Mean?

Taranabant is a cannabinoid 1 receptor inverse agonist that is also known as MK-0364. It was developed by Merck & Co. for use as a potential drug to combat obesity and to help in weight loss. However, clinical trials were stopped in 2008 because of side effects such as anxiety, depression, and other central nervous system disorders.

Maximum Yield Explains Taranabant

Taranabant, in clinical studies performed with 500 participants, caused weight loss in all participants that took the drug. The most amount of weight was lost by participants that took the most of the drug. After 12 weeks, the average amount of weight loss in the test group was 11.6 lbs. Developing this drug was used under the neurochemical premise that blocking of the rewards system of the eating process with a drug would reduce food consumption, and thus encourage weight loss. However, it wasn't as popular in the United States.

According to Merck’s senior vice-president, John Amatruda, data gathered from Phase III of the Taranabant study showed that the drug was far more efficient in higher doses. But, higher doses also increased adverse effects in patients.